Who is eligible for clinical trial NCT05583227?

Participants must meet protocol criteria for Eosinophilic Esophagitis. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05583227 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-29

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis (NCT05583227)

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).

Who can join: Review the eligibility criteria below.

Location: Research Site — Phoenix, Arizona

Age range: 12 Years to 80 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (124 Sites)

Showing the first 25 of 124 sites.

Research Site — Phoenix, Arizona
Research Site — Little Rock, Arkansas
Research Site — Los Angeles, California
Research Site — Aurora, Colorado
Research Site — Inverness, Florida
Research Site — Jacksonville, Florida
Research Site — Saint Augustine, Florida
Research Site — Normal, Illinois
Research Site — Iowa City, Iowa
Research Site — Topeka, Kansas
Research Site — White Marsh, Maryland
Research Site — Boston, Massachusetts
Research Site — Chesterfield, Michigan
Research Site — Lincoln, Nebraska
Research Site — Ocean City, New Jersey
Research Site — Brooklyn, New York
Research Site — Chapel Hill, North Carolina
Research Site — Cincinnati, Ohio
Research Site — Philadelphia, Pennsylvania
Research Site — Uniontown, Pennsylvania
Research Site — Nashville, Tennessee
Research Site — Houston, Texas
Research Site — Salt Lake City, Utah
Research Site — Salt Lake City, Utah
Research Site — Elizabeth Vale,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Eosinophilic Esophagitis

Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children — Chicago, Illinois
A Prospective Study of the Four Food Elimination Diet for Treatment of Eosinophilic Esophagitis — Chicago, Illinois
Dupilumab for Eosinophilic Esophagitis With Severe Strictures — Chapel Hill, North Carolina
Cow's Milk Elimination for Treatment of Eosinophilic Esophagitis — Chicago, Illinois
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks — Little Rock, Arkansas

Explore by condition: All Eosinophilic Esophagitis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗